# Anavex Life Sciences Corp.: financial statements, quarterly

AVXL · Nasdaq · CIK 1314052 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/avxl.md) · [Financials](/companies/avxl/financials.md) · [Filings](/companies/avxl/filings.md) · [Insiders](/companies/avxl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avxl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [10.1 d](/filings/0001731122-26-001164.md) | [8.7](/filings/0001731122-25-000205.md) | [9.7](/filings/0001731122-25-000724.md) | [11.8](/filings/0001731122-25-001105.md) | [11.6 d](/filings/0001731122-26-001164.md) | [10.4](/filings/0001731122-26-000200.md) | [9.9](/filings/0001731122-26-001166.md) | [10.0](/filings/0001731122-25-001105.md) | [7.3 d](/filings/0001731122-26-001164.md) | [4.7](/filings/0001731122-26-000200.md) | [4.2](/filings/0001731122-26-001166.md) | not reported |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | [3.1](/filings/0001731122-26-000200.md) | [2.6](/filings/0001731122-26-001166.md) | [4.5](/filings/0001731122-26-001167.md) | [3.6 d](/filings/0001731122-26-001164.md) | [2.1](/filings/0001731122-26-000200.md) | [2.3](/filings/0001731122-26-001166.md) | [2.0](/filings/0001731122-26-001167.md) |
| Operating income | $m | [(12.7) d](/filings/0001731122-26-001164.md) | [(11.4)](/filings/0001731122-25-000205.md) | [(12.6)](/filings/0001731122-25-000724.md) | [(14.6)](/filings/0001731122-25-001105.md) | [(14.3) d](/filings/0001731122-26-001164.md) | [(13.6)](/filings/0001731122-26-000200.md) | [(12.5)](/filings/0001731122-26-001166.md) | [(14.5)](/filings/0001731122-26-001167.md) | [(10.8) d](/filings/0001731122-26-001164.md) | [(6.8)](/filings/0001731122-26-000200.md) | [(6.5)](/filings/0001731122-26-001166.md) | [6.7](/filings/0001731122-26-001167.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001731122-26-000200.md) | [0.0 d](/filings/0001731122-26-001166.md) | [0.0 d](/filings/0001731122-26-001167.md) |
| Net income | $m | [(10.1) d](/filings/0001731122-26-001164.md) | [(8.6)](/filings/0001731122-25-000205.md) | [(10.5)](/filings/0001731122-25-000724.md) | [(12.2)](/filings/0001731122-25-001105.md) | [(11.6) d](/filings/0001731122-26-001164.md) | [(12.1)](/filings/0001731122-26-000200.md) | [(11.2)](/filings/0001731122-26-001166.md) | [(13.2)](/filings/0001731122-26-001167.md) | [(9.8) d](/filings/0001731122-26-001164.md) | [(5.7)](/filings/0001731122-26-000200.md) | [(5.3)](/filings/0001731122-26-001166.md) | [7.8](/filings/0001731122-26-001167.md) |
| Diluted EPS | $ per share | not reported | [(0.11)](/filings/0001731122-25-000205.md) | [(0.13)](/filings/0001731122-25-000724.md) | [(0.14)](/filings/0001731122-25-001105.md) | not reported | [(0.14)](/filings/0001731122-26-000200.md) | [(0.13)](/filings/0001731122-26-001166.md) | [(0.16)](/filings/0001731122-26-001167.md) | not reported | [(0.06)](/filings/0001731122-26-000200.md) | [(0.06)](/filings/0001731122-26-001166.md) | [0.08](/filings/0001731122-26-001167.md) |
| Basic EPS | $ per share | not reported | [(0.11)](/filings/0001731122-25-000205.md) | [(0.13)](/filings/0001731122-25-000724.md) | [(0.14)](/filings/0001731122-25-001105.md) | not reported | [(0.14)](/filings/0001731122-26-000200.md) | [(0.13)](/filings/0001731122-26-001166.md) | [(0.16)](/filings/0001731122-26-001167.md) | not reported | [(0.06)](/filings/0001731122-26-000200.md) | [(0.06)](/filings/0001731122-26-001166.md) | [0.08](/filings/0001731122-26-001167.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [151](/filings/0001731122-24-002041.md) | [144](/filings/0001731122-24-000206.md) | [139](/filings/0001731122-24-000760.md) | [139](/filings/0001731122-24-001207.md) | [132](/filings/0001731122-26-001164.md) | [121](/filings/0001731122-25-000205.md) | [116](/filings/0001731122-25-000724.md) | [101](/filings/0001731122-25-001105.md) | [103](/filings/0001731122-26-001167.md) | [132](/filings/0001731122-26-000200.md) | [127](/filings/0001731122-26-001166.md) | [118](/filings/0001731122-26-001167.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [154](/filings/0001731122-24-002041.md) | [148](/filings/0001731122-24-000206.md) | [145](/filings/0001731122-24-000760.md) | [142](/filings/0001731122-24-001207.md) | [136](/filings/0001731122-26-001164.md) | [124](/filings/0001731122-25-000205.md) | [117](/filings/0001731122-25-000724.md) | [102](/filings/0001731122-25-001105.md) | [104](/filings/0001731122-26-001167.md) | [133](/filings/0001731122-26-000200.md) | [129](/filings/0001731122-26-001166.md) | [120](/filings/0001731122-26-001167.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total liabilities | $m | [12.5](/filings/0001731122-24-002041.md) | [12.5](/filings/0001731122-24-000206.md) | [9.6](/filings/0001731122-24-000760.md) | [11.8](/filings/0001731122-24-001207.md) | [15.3](/filings/0001731122-26-001164.md) | [13.1](/filings/0001731122-25-000205.md) | [17.4](/filings/0001731122-25-000724.md) | [11.5](/filings/0001731122-25-001105.md) | [8.9](/filings/0001731122-26-001167.md) | [6.4](/filings/0001731122-26-000200.md) | [7.1](/filings/0001731122-26-001166.md) | [7.7](/filings/0001731122-26-001167.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [142](/filings/0001731122-26-001164.md) | [136](/filings/0001731122-25-000724.md) | [135](/filings/0001731122-25-001105.md) | [130](/filings/0001731122-25-001105.md) | [120](/filings/0001731122-26-001167.md) | [111](/filings/0001731122-26-001166.md) | [99.8](/filings/0001731122-26-001167.md) | [91.0](/filings/0001731122-26-001167.md) | [94.9](/filings/0001731122-26-001167.md) | [127](/filings/0001731122-26-001166.md) | [122](/filings/0001731122-26-001167.md) | [112](/filings/0001731122-26-001167.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: not reported
- Total assets: us-gaap:Assets
- Current liabilities: not reported
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.8) d](/filings/0001731122-26-001164.md) | [(7.3)](/filings/0001731122-25-000205.md) | [(11.7) d](/filings/0001731122-25-000724.md) | [(5.2) d](/filings/0001731122-25-001105.md) | [(6.7) d](/filings/0001731122-26-001164.md) | [(12.1)](/filings/0001731122-26-000200.md) | [(5.9) d](/filings/0001731122-26-001166.md) | [(12.5) d](/filings/0001731122-26-001167.md) | [(8.6) d](/filings/0001731122-26-001164.md) | [(7.2)](/filings/0001731122-26-000200.md) | [(4.4) d](/filings/0001731122-26-001166.md) | [(9.1) d](/filings/0001731122-26-001167.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | billions of shares | [0.1](/filings/0001731122-24-000206.md) | [0.1](/filings/0001731122-24-000760.md) | [0.1](/filings/0001731122-24-001207.md) | [0.1](/filings/0001731122-25-000205.md) | [0.1](/filings/0001731122-25-000724.md) | [0.1](/filings/0001731122-25-001105.md) | [0.1](/filings/0001731122-26-000200.md) | [0.1](/filings/0001731122-26-001166.md) | [85.4](/filings/0001731122-26-001167.md) | [0.1](/filings/0001731122-26-000200.md) | [0.1](/filings/0001731122-26-001166.md) | [92.9](/filings/0001731122-26-001167.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 92,696,842 at 2026-08-28, from the cover of the [10-Q filed 2026-08-28](/filings/0001731122-26-001167.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.